CardioAI: A Multimodal AI-based System to Support Symptom Monitoring and Risk Detection of Cancer Treatment-Induced Cardiotoxicity

Despite recent advances in cancer treatments that prolong patients' lives, treatment-induced cardiotoxicity remains one severe side effect. The clinical decision-making of cardiotoxicity is challenging, as non-clinical symptoms can be missed until life-threatening events occur at a later stage, and clinicians already have a high workload centered on the treatment, not the side effects. Our project starts with a participatory design study with 11 clinicians to understand their practices and needs; then we build a multimodal AI system, CardioAI, that integrates wearables and LLM-powered voice assistants to monitor multimodal non-clinical symptoms. Also, the system includes an explainable risk prediction module that can generate cardiotoxicity risk scores and summaries as explanations to support clinicians' decision-making. We conducted a heuristic evaluation with four clinical experts and found that they all believe CardioAI integrates well into their workflow, reduces their information overload, and enables them to make more informed decisions.